Viking Therapeutics' stock price surged nearly 12% in a single day, driven by investor optimism over comments suggesting the weight-loss drug market is larger than currently visible, indicating robust future prospects. The stock's performance was highlighted as one of the top market gainers. Notably, financial commentator Jim Cramer, when asked about the company, stated a personal preference for competitor Eli Lilly but acknowledged the stock's significant move.